Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).

被引：0
|
作者：
Chen, Xiaofeng
Wang, Deqiang
Yuan, Yuan
Tang, Jie
Guo, Fen
Chen, Yizhang
Ding, Junli
Hong, Tingting
Lu, Binbin
Li, Wei
Wang, Rong
Tian, Yitong
Pan, Lanlan
Zhang, Jiaguang
Zhang, Xinyi
Xu, Tongpeng
Xu, Hao
Shu, Yongqian
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Peoples R China
[2] Jiangsu Univ, Affiliated Hosp, Canc Therapy Ctr, Dept Med Oncol, Zhenjiang, Jiangsu, Peoples R China
[3] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China
[4] Jiangsu Peoples Hosp, Liyang Branch, Dept Oncol, Liyang, Peoples R China
[5] Suzhou Municipal Hosp, Dept Oncol, Suzhou, Peoples R China
[6] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Peoples R China
[7] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China
[8] Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Affiliated Hosp 2, Dept Med Oncol, Nanjing, Peoples R China
[10] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China
[11] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
396
引用
收藏
页码：396 / 396
页数：1
相关论文
共 50 条
  • [31] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [32] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [33] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [34] Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
    Calabro, Luana
    Morra, Aldo
    Fonsatti, Ester
    Cutaia, Ornella
    Amato, Giovanni
    Giannarelli, Diana
    Di Giacomo, Anna Maria
    Danielli, Riccardo
    Altomonte, Maresa
    Mutti, Luciano
    Maio, Michele
    LANCET ONCOLOGY, 2013, 14 (11): : 1104 - 1111
  • [35] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Wang, Rui-Rui
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367
  • [36] Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial
    Marandino, L.
    Raggi, D.
    Calareso, G.
    Alessi, A.
    Colecchia, M.
    Martini, A.
    Briganti, A.
    Montorsi, F.
    Madison, R.
    Ross, J. S.
    Necchi, A.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 457 - 465
  • [37] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Qi Yu
    Meng Xiangrui
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [39] Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study
    Wang, Qi
    Deng, Siyou
    Shen, Qian
    Zhang, Ni
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
    Marron, Thomas U.
    Fiel, Maria Isabel
    Hamon, Pauline
    Fiaschi, Nathalie
    Kim, Edward
    Ward, Stephen C.
    Zhao, Zhen
    Kim, Joel
    Kennedy, Paul
    Gunasekaran, Ganesh
    Tabrizian, Parissa
    Doroshow, Deborah
    Legg, Meredith
    Hammad, Ashley
    Magen, Assaf
    Kamphorst, Alice O.
    Shareef, Muhammed
    Gupta, Namita T.
    Deering, Raquel
    Wang, Wei
    Wang, Fang
    Thanigaimani, Pradeep
    Mani, Jayakumar
    Troncoso, Leanna
    Tabachnikova, Alexandra
    Chang, Christie
    Akturk, Guray
    Buckup, Mark
    Hamel, Steven
    Ioannou, Giorgio
    Hennequin, Clotilde
    Jamal, Hajra
    Brown, Haley
    Bonaccorso, Antoinette
    Labow, Daniel
    Sarpel, Umut
    Rosenbloom, Talia
    Sung, Max W.
    Kou, Baijun
    Li, Siyu
    Jankovic, Vladimir
    James, Nicola
    Ham, Sara C.
    Cheung, Hung Kam
    Sims, Jennifer S.
    Miller, Elizabeth
    Bhardwaj, Nina
    Thurston, Gavin
    Lowy, Israel
    Gnjatic, Sacha
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 219 - 229
12345